{"filings":[{"id":815636,"accession_number":"0001437749-26-019262","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2026-06-03T11:34:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"TG Therapeutics reports positive Phase 1 data for subcutaneous BRIUMVI; bioavailability >60% vs IV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean bioavailability >60% relative to IV; lower bound of 95% CI >55%.","PK modeling predicts non-inferior total drug exposure for quarterly SC dosing (GMR 1.21, lower 90% CI 1.15).","Subcutaneous BRIUMVI well tolerated; injection-site reactions <5%, no new safety signals.","B-cell depletion with SC consistent with IV; supports biologic activity.","Phase 3 fully enrolled; top-line data expected late 2026 or early 2027; potential approval in 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":696677,"accession_number":"0001437749-26-018586","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2026-05-27T20:34:57+00:00","items":["8.01","9.01"],"status":"ready","headline":"TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.","Safety and tolerability of consolidated first infusion were consistent with established BRIUMVI profile; no Grade 3 or higher infusion reactions occurred.","Supplemental BLA submission targeted for second half of 2026 based on these results.","If approved, BRIUMVI would be the first and only IV anti-CD20 therapy initiated with a single infusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90501,"accession_number":"0001437749-26-015013","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics Q1 BRIUMVI US rev $194.8M; raises FY guidance to $885-900M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 total global revenue approx $205M; BRIUMVI U.S. net product revenue $194.8M (+63% YoY).","Net income $19.8M vs $5.1M YoY; product revenue $201.3M vs $119.7M YoY.","Raises FY 2026 BRIUMVI U.S. net product revenue target to $885-900M; Q2 target ~$220M.","Cash $572.8M at March 31, 2026; repurchased $100M of stock in Q1 at avg $29.28/share.","Pipeline: ENHANCE Phase 3 data mid-2026; subcutaneous BRIUMVI data year-end 2026/Q1 2027; azer-cel data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":204918000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100060,"accession_number":"0001437749-26-009253","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"TG Therapeutics establishes $750M term loan facility due 2031, repays prior term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $750M on March 18, 2026 under new term loan; proceeds used to fully repay initial term loans.","Loan matures March 18, 2031; interest rate is SOFR + margin starting at 4.75% (or base rate + 3.75%).","Quarterly amortization payments of $37.5M begin Q1 2030; can be deferred if leverage ratio met.","Also established uncommitted additional facility of up to $250M.","Loan secured by substantially all assets of borrower and guarantors; includes customary covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100059,"accession_number":"0001437749-26-005733","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics Q4 BRIUMVI US revenue $182.7M (+20% QoQ); 2026 revenue guidance raised to $875-900M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $192.6M; full year 2025 $616.3M; BRIUMVI US net revenue $594.1M (+92% YoY).","Net income Q4 $23.0M; full year $447.2M including $339.8M non-recurring deferred tax asset benefit.","2026 guidance: total global revenue $875-900M; BRIUMVI US net $825-850M; Q1 2026 target $185-190M.","Completed $100M share repurchase (3.5M shares at avg $28.55); new $100M buyback authorized.","Pipeline milestones: ENHANCE IV data mid-2026; subcutaneous ublituximab data year-end 2026/1Q 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":2.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":616287000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100058,"accession_number":"0001437749-26-001194","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TG Therapeutics prelim FY2025 global rev ~$616M; 2026 guided $875-900M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary FY2025 total global revenue ~$616M; U.S. BRIUMVI net product rev Q4 ~$182M, FY ~$594M.","2026 target total global revenue $875-900M; U.S. BRIUMVI net product rev $825-850M.","2026 operating expense target ~$350M (excl. SBC) + ~$100M for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up.","Pipeline milestones: ENHANCE IV BRIUMVI trial data mid-2026; subcutaneous BRIUMVI topline year-end 2026/1Q 2027; azer-cel Phase 1 data in Progressive MS H2 2026.","Plans to commence registration-directed trial for BRIUMVI outside MS and additional exploratory studies in autoimmune disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116403,"accession_number":"0001437749-25-032658","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics raises BRIUMVI revenue guidance to $585M, Q3 net income $390.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 total revenue $161.7M, BRIUMVI US net revenue $152.9M up 84% YoY.","Raises FY2025 BRIUMVI US net revenue target to ~$585M (prior $570-575M) and global target to $600M.","Q3 net income $390.9M includes $365M non-recurring tax benefit; net income $3.9M in Q3 2024.","Completed $100M buyback (3.5M shares at avg $28.55); authorized new $100M repurchase program.","Phase 3 subcutaneous ublituximab enrollment commenced; ENHANCE trial for consolidated IV dosing fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":2.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":423713000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132853,"accession_number":"0001437749-25-024480","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics Q2 BRIUMVI revenue $138.8M (+91% YoY); raises FY guidance to $570-575M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total revenue $141.1M; BRIUMVI U.S. net sales $138.8M, up 91% YoY vs $72.6M.","Net income $28.2M in Q2 2025 vs $6.9M in Q2 2024; cash and securities $278.9M.","Raises FY 2025 BRIUMVI U.S. net revenue guidance to $570-575M (prior $560M); total global revenue target ~$585M.","R&D expense $31.8M (up from $17.6M) driven by subcutaneous development; SG&A $55.6M (up from $38.8M) for commercialization.","Pipeline: Phase 3 ENHANCE trial for consolidated IV dosing ongoing; Phase 1 azer-cel in autoimmune diseases first patient dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":262004000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149404,"accession_number":"0001437749-25-020335","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"TG Therapeutics annual meeting: all proposals pass; say-on-pay gets 54.5% support, director Lonial 54.1%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six directors elected; Sagar Lonial, MD had lowest support (54.12% for, 40.5M withheld).","KPMG ratified as independent auditor for FY2025 with 117.8M for (99.6% approval).","Advisory vote on named executive officer compensation passed with 47.9M for (54.5% of votes cast).","2022 Incentive Plan amended to increase authorized shares from 17M to 22M (82.0M for vs 5.8M against).","Quorum of 118.4M shares (74.58%) represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149403,"accession_number":"0001437749-25-014402","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics Q1 BRIUMVI sales $119.7M (+137% YoY); raises FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 BRIUMVI U.S. net revenue $119.7M vs $50.5M YoY, up ~137%.","Net income $5.1M vs net loss $10.7M in Q1 2024; GAAP improvement.","Raises FY2025 BRIUMVI U.S. net revenue target to ~$560M (prior $525M).","Raises FY2025 total global revenue target to ~$575M (prior $540M).","Q2 2025 BRIUMVI U.S. net revenue target set at $135M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":120856000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168466,"accession_number":"0001437749-25-005802","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.","Net income of $23.3M in Q4 2024 vs net loss of $14.4M in Q4 2023; full year net income $23.4M.","2025 guidance: total global revenue ~$540M, including BRIUMVI U.S. net revenue ~$525M; operating expenses ~$300M.","Cash, cash equivalents and investments $311M as of Dec 31, 2024; company expects sufficient funding from revenues.","Pipeline: Phase 1 trials for subcutaneous ublituximab in MS and MG; licensed azer-cel CAR T for autoimmune indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168465,"accession_number":"0001437749-25-001106","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"TG Therapeutics Prelim. Q4 BRIUMVI Rev $103.6M; FY2025 US Revenue Target $525M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2024 BRIUMVI U.S. net product revenue $103.6M; full year 2024 $310M.","FY2025 target total global revenue ~$540M, including BRIUMVI U.S. net product revenue ~$525M; target opex ~$300M.","2025 milestones: commence pivotal program for subcutaneous BRIUMVI; evaluate 30-min infusion; enroll in autoimmune trials.","Year-end 2024 cash position approx. $310M.","CEO states 2024 revenue far exceeded initial expectations; BRIUMVI well positioned for continued growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185600,"accession_number":"0001437749-24-033055","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics Q3 BRIUMVI revenue $83.3M, raises FY2024 guidance to $300-$305M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BRIUMVI Q3 U.S. net sales $83.3M, up 15% QoQ and 230% YoY; full-year target raised to $300-$305M.","Net income $3.9M in Q3 vs $113.9M a year ago (prior period included $140M upfront payment); cash $341M.","Phase 1 trial of subcutaneous ublituximab initiated; FDA cleared IND for azer-cel in progressive MS.","Secured FUJIFILM Diosynth as secondary U.S. manufacturer of BRIUMVI.","Five-year ECTRIMS data: 92% of patients free from disability progression; annualized relapse rate 0.02."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":220819000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202177,"accession_number":"0001437749-24-024718","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["1.01","1.02","2.2","2.02","8.01","9.01"],"status":"ready","headline":"TG Therapeutics Q2 BRIUMVI rev $72.6M, raises guidance; $250M credit facility; material weakness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 BRIUMVI net revenue $72.6M (+350% YoY); net income $6.9M vs loss $47.6M.","Raises FY 2024 BRIUMVI revenue target to ~$290-300M, up from $270-290M.","New $250M term loan repays $107M Hercules debt; $100M share repurchase authorized.","Material weakness in ICFR from 2021 restricted stock grant error; immaterial to financials; 10-K/A to be filed.","Phase 1 subcutaneous ublituximab in RMS initiated; FDA IND clearance for azer-cel in progressive MS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":136939000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218233,"accession_number":"0001437749-24-020510","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"TG Therapeutics shareholders approve share increase and incentive plan amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increasing authorized common stock from 175M to 190M (73.8M for, 36.3M against).","Shareholders approved amendment to 2022 Incentive Plan removing full-value award limit (66.7M for, 8.6M against).","Two director nominees (Yann Echelard, Daniel Hume) each received less than 50% of votes cast for election.","Advisory say-on-pay proposal passed with 55.6% support (42.3M for, 31.0M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218232,"accession_number":"0001437749-24-014062","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics Q1 BRIUMVI revenue $50.5M, raises FY guidance to $270-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BRIUMVI U.S. net revenue $50.5M in Q1 2024, >25% QoQ growth; total revenue $63.5M includes $12.5M EU launch milestone.","Net loss improved to $10.7M from $39.2M in Q1 2023; cash position $209.8M as of March 31, 2024.","Raised FY 2024 BRIUMVI U.S. net revenue guidance to $270-290M (prior $220-260M) with Q2 target ~$65M.","Over 1,250 new BRIUMVI prescriptions in Q1; VA national formulary contract secured for anti-CD20 indications.","R&D spend $32.7M includes $8.8M license fee for azer-cel allogeneic CAR-T from Precision BioSciences."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":63474000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238199,"accession_number":"0001437749-24-005802","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.","Net loss of $14.4M in Q4; net income of $12.7M for full year 2023.","Year-end cash $217.5M; 2024 BRIUMVI net revenue target $220-260M; operating expense ~$250M.","License revenue $141.7M in 2023 driven by $140M Neuraxpharm payment for ex-U.S. rights.","Pipeline: subcutaneous BRIUMVI, azer-cel CAR T in autoimmune disease to start trials in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":233662000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238198,"accession_number":"0001437749-24-001061","cik":1001316,"company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.","Preliminary Q4 2023 BRIUMVI U.S. net product revenue ~$40M, full year ~$89M; year-end cash ~$215M.","2024 guidance: BRIUMVI U.S. net product revenue target $220-260M, Q1 target $41-46M; operating expense ~$250M.","2024 pipeline milestones: start trials for subcutaneous BRIUMVI, BRIUMVI in other autoimmune diseases, and azer-cel in autoimmune disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6000875968.567834,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}